Equity
Retained Earnings
Regeneron Pharmaceuticals Retained Earnings increased by 1.8% to $36.42B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.5%, from $32.38B to $36.42B. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows an upward trend with a 26.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase signals strong historical profitability and reinvestment, while a decrease may indicate losses or significant dividend payouts.
Detailed definition
This represents the cumulative net income earned by the company since its inception, minus any dividends paid to shareho...
Peer comparison
A key metric for all established companies; growth rates are compared against peers to gauge long-term success.
Metric ID:
retained_earningsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.11B | $16.74B | $18.97B | $19.94B | $20.79B | $22.11B | $23.31B | $24.12B | $25.09B | $26.10B | $27.26B | $27.98B | $29.41B | $30.76B | $31.67B | $32.38B | $33.68B | $35.05B | $35.80B | $36.42B |
| QoQ Change | — | +10.8% | +13.3% | +5.1% | +4.3% | +6.3% | +5.4% | +3.5% | +4.0% | +4.0% | +4.4% | +2.6% | +5.1% | +4.6% | +3.0% | +2.2% | +4.0% | +4.1% | +2.1% | +1.8% |
| YoY Change | — | — | — | — | +37.6% | +32.1% | +22.9% | +21.0% | +20.7% | +18.1% | +17.0% | +16.0% | +17.2% | +17.8% | +16.2% | +15.7% | +14.5% | +14.0% | +13.0% | +12.5% |
Range$15.11B – $36.42B
CAGR+20.4%
Avg YoY Growth+19.1%
Median YoY Growth+17.1%
Current Streak19+ quarters growth
Retained Earnings at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's retained earnings?
- Regeneron Pharmaceuticals (REGN) reported retained earnings of $36.42B in Q1 2026.
- How has Regeneron Pharmaceuticals's retained earnings changed year-over-year?
- Regeneron Pharmaceuticals's retained earnings increased by 12.5% year-over-year, from $32.38B to $36.42B.
- What is the long-term trend for Regeneron Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's retained earnings has grown at a 26.9% compound annual growth rate (CAGR), from $10.89B to $35.80B.
- What does retained earnings mean?
- The total accumulated profits the company has kept and reinvested rather than paying out as dividends.